Abbott Defeated In HCV Patent Feud

Law360, New York (September 5, 2006, 12:00 AM EDT) -- Proving that its optimism was well-founded, Belgian biotechnology company Innogenetics N.V. has been handed a victory in its long-running battle with Abbott Laboratories over a hepatitis C virus genotyping patent.

On Friday, a jury in the U.S. District Court for the Western District of Wisconsin upheld Innogenetics' HCV patent, ruling that the intellectual property in dispute was valid.

"We are very gratified with the jury's decision that affirmed the validity of a very important patent to our company,” said Innogenetics Chief Executive Frank Morich. “We are...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.